
Gregory Berger
Greg has been at the cell and Gene Therapy Catapult since early 2017 and brings a wealth expertise in viral vector/cell line development, vector production in bioreactors and development of appropriate analytical tools for characterisation and functionality assessment. Greg obtained his PhD in Virology and Immunology from the Ecole Normale Superieure de Lyon (ENS Lyon) in France, focussing upon the development of new Lentiviral vectors for the development of Dendritic cell-based immunotherapy. He then joined the department of Immunobiology and Infectious Disease at King’s College London as a post-doctoral researcher where his work focussed predominantly on viral vector integration and immune cell dysfunction upon transduction. At CGTC, Greg is currently working with the process and analytical team to address the current challenges regarding viral vector manufacturing.